Age Related Macular Degeneration Market By Drug Type , By Disease Type (Wet Age Related Macular Degeneration , Dry Age Related Macular Degeneration ) By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

Age Related Macular Degeneration Market

The age related macular degeneration market was valued at $10.0 billion in 2023 and is projected to reach $16.2 billion by 2033, growing at a CAGR of 5% from 2024 to 2033.

Age related macular degeneration is a visual impairment in which the central portion of the retina, known as macula, deteriorates. Beginning with slight blurred vision, the disease eventually leads to loss of central eyesight. There are two categories of the disease: dry (atrophic) and wet (neovascular). Gradual thinning of the macula occurs in dry macular degeneration, whereas wet macular degeneration happens due to abnormal growth of blood vessels under the retina.

Exponential increase in the aging population and rise in prevalence of the disease are the key drivers of the age related macular degeneration market. In addition, advancements in diagnostic techniques are leading to early detection and timely treatment of the disease, thereby augmenting the market development. In recent times, AI and deep learning are revolutionizing the landscape of age related macular degeneration diagnosis and treatment. The technology helps in precise detection of the eye condition and assesses the risk pertaining to the progression of the disease to advanced stages.

However, in case of disease advancement to high stages, treatment procedures exhibit limited to no efficacy, thereby restraining the growth of the age related macular degeneration market. Moreover, the high expense of purchasing medications essential for curing the disease, such as anti-vascular endothelial growth factor injections, constraints several patients from undergoing the treatment. This hampers the development of the market. According to an article published by the UK-based scientific journals publisher-BioMed Central- age related macular degeneration is one of the leading causes of vision loss and by 2040, the disease is anticipated to impact 288 million individuals.

Segment Review

The age related macular degeneration market is segmented into drug type, disease type, distribution channel, and region. On the basis of drug type, the market is divided into aflibercept, ranibizumab, and others. Depending on disease type, it is bifurcated into wet age related macular degeneration (AMD) and dry age related macular degeneration (AMD). As per distribution channel, it is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of drug type, the aflibercept segment dominates the age related macular degeneration market.

Depending on disease type, the wet age-related macular degeneration (AMD) segment acquires a significant share of the market.

As per distribution channel, the hospital pharmacy segment leads in the market.

Region wise, the market exhibits robust growth in North America.

Competition Analysis

The leading players operating in the global age related macular degeneration market include Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Biogen, Bayer AG, Coherus Biosciences Inc, Sanofi, Apellis Pharmaceuticals, Bausch Health Companies Inc., and Ionis Pharmaceuticals, Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Expanded list for Company Profiles
Historic market data

Key Market Segments

By Drug Type

Aflibercept
Ranibizumab
Others

By Disease Type

Wet Age Related Macular Degeneration (AMD)
Dry Age Related Macular Degeneration (AMD)

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA

Key Market Players:

Regeneron Pharmaceuticals Inc.
Novartis AG
F. Hoffmann-La Roche Ltd.
Biogen
Bayer AG
Coherus Biosciences Inc
Sanofi
Apellis Pharmaceuticals
Bausch Health Companies Inc.
Ionis Pharmaceuticals, Inc

Product Code: A201849

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Drug Type
4.2. Aflibercept
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
4.3. Ranibizumab
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
4.4. Others
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country

CHAPTER 5: AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Disease Type
5.2. Wet Age Related Macular Degeneration (AMD)
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
5.3. Dry Age Related Macular Degeneration (AMD)
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country

CHAPTER 6: AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Distribution Channel
6.2. Hospital Pharmacy
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
6.3. Retail Pharmacy
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
6.4. Online Pharmacy
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country

CHAPTER 7: AGE RELATED MACULAR DEGENERATION MARKET, BY REGION

7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Drug Type
- 7.2.3. Market Size and Forecast, By Disease Type
- 7.2.4. Market Size and Forecast, By Distribution Channel
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Age Related Macular Degeneration Market
  - 7.2.6.1. Market Size and Forecast, By Drug Type
  - 7.2.6.2. Market Size and Forecast, By Disease Type
  - 7.2.6.3. Market Size and Forecast, By Distribution Channel
- 7.2.7. Canada Age Related Macular Degeneration Market
  - 7.2.7.1. Market Size and Forecast, By Drug Type
  - 7.2.7.2. Market Size and Forecast, By Disease Type
  - 7.2.7.3. Market Size and Forecast, By Distribution Channel
- 7.2.8. Mexico Age Related Macular Degeneration Market
  - 7.2.8.1. Market Size and Forecast, By Drug Type
  - 7.2.8.2. Market Size and Forecast, By Disease Type
  - 7.2.8.3. Market Size and Forecast, By Distribution Channel
7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Drug Type
- 7.3.3. Market Size and Forecast, By Disease Type
- 7.3.4. Market Size and Forecast, By Distribution Channel
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. France Age Related Macular Degeneration Market
  - 7.3.6.1. Market Size and Forecast, By Drug Type
  - 7.3.6.2. Market Size and Forecast, By Disease Type
  - 7.3.6.3. Market Size and Forecast, By Distribution Channel
- 7.3.7. Germany Age Related Macular Degeneration Market
  - 7.3.7.1. Market Size and Forecast, By Drug Type
  - 7.3.7.2. Market Size and Forecast, By Disease Type
  - 7.3.7.3. Market Size and Forecast, By Distribution Channel
- 7.3.8. Italy Age Related Macular Degeneration Market
  - 7.3.8.1. Market Size and Forecast, By Drug Type
  - 7.3.8.2. Market Size and Forecast, By Disease Type
  - 7.3.8.3. Market Size and Forecast, By Distribution Channel
- 7.3.9. Spain Age Related Macular Degeneration Market
  - 7.3.9.1. Market Size and Forecast, By Drug Type
  - 7.3.9.2. Market Size and Forecast, By Disease Type
  - 7.3.9.3. Market Size and Forecast, By Distribution Channel
- 7.3.10. UK Age Related Macular Degeneration Market
  - 7.3.10.1. Market Size and Forecast, By Drug Type
  - 7.3.10.2. Market Size and Forecast, By Disease Type
  - 7.3.10.3. Market Size and Forecast, By Distribution Channel
- 7.3.11. Rest of Europe Age Related Macular Degeneration Market
  - 7.3.11.1. Market Size and Forecast, By Drug Type
  - 7.3.11.2. Market Size and Forecast, By Disease Type
  - 7.3.11.3. Market Size and Forecast, By Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Drug Type
- 7.4.3. Market Size and Forecast, By Disease Type
- 7.4.4. Market Size and Forecast, By Distribution Channel
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. China Age Related Macular Degeneration Market
  - 7.4.6.1. Market Size and Forecast, By Drug Type
  - 7.4.6.2. Market Size and Forecast, By Disease Type
  - 7.4.6.3. Market Size and Forecast, By Distribution Channel
- 7.4.7. Japan Age Related Macular Degeneration Market
  - 7.4.7.1. Market Size and Forecast, By Drug Type
  - 7.4.7.2. Market Size and Forecast, By Disease Type
  - 7.4.7.3. Market Size and Forecast, By Distribution Channel
- 7.4.8. India Age Related Macular Degeneration Market
  - 7.4.8.1. Market Size and Forecast, By Drug Type
  - 7.4.8.2. Market Size and Forecast, By Disease Type
  - 7.4.8.3. Market Size and Forecast, By Distribution Channel
- 7.4.9. South Korea Age Related Macular Degeneration Market
  - 7.4.9.1. Market Size and Forecast, By Drug Type
  - 7.4.9.2. Market Size and Forecast, By Disease Type
  - 7.4.9.3. Market Size and Forecast, By Distribution Channel
- 7.4.10. Australia Age Related Macular Degeneration Market
  - 7.4.10.1. Market Size and Forecast, By Drug Type
  - 7.4.10.2. Market Size and Forecast, By Disease Type
  - 7.4.10.3. Market Size and Forecast, By Distribution Channel
- 7.4.11. Rest of Asia-Pacific Age Related Macular Degeneration Market
  - 7.4.11.1. Market Size and Forecast, By Drug Type
  - 7.4.11.2. Market Size and Forecast, By Disease Type
  - 7.4.11.3. Market Size and Forecast, By Distribution Channel
7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Drug Type
- 7.5.3. Market Size and Forecast, By Disease Type
- 7.5.4. Market Size and Forecast, By Distribution Channel
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Age Related Macular Degeneration Market
  - 7.5.6.1. Market Size and Forecast, By Drug Type
  - 7.5.6.2. Market Size and Forecast, By Disease Type
  - 7.5.6.3. Market Size and Forecast, By Distribution Channel
- 7.5.7. South Africa Age Related Macular Degeneration Market
  - 7.5.7.1. Market Size and Forecast, By Drug Type
  - 7.5.7.2. Market Size and Forecast, By Disease Type
  - 7.5.7.3. Market Size and Forecast, By Distribution Channel
- 7.5.8. Saudi Arabia Age Related Macular Degeneration Market
  - 7.5.8.1. Market Size and Forecast, By Drug Type
  - 7.5.8.2. Market Size and Forecast, By Disease Type
  - 7.5.8.3. Market Size and Forecast, By Distribution Channel
- 7.5.9. Rest of LAMEA Age Related Macular Degeneration Market
  - 7.5.9.1. Market Size and Forecast, By Drug Type
  - 7.5.9.2. Market Size and Forecast, By Disease Type
  - 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. Regeneron Pharmaceuticals Inc.
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
9.2. Novartis AG
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
9.3. F. Hoffmann-La Roche Ltd.
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
9.4. Biogen
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
9.5. Bayer AG
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
9.6. Coherus Biosciences Inc
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
9.7. Sanofi
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
9.8. Apellis Pharmaceuticals
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
9.9. Bausch Health Companies Inc.
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
9.10. Ionis Pharmaceuticals, Inc
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments